Inflammation therapy - Merck KGaA/SkyePharma

Drug Profile

Inflammation therapy - Merck KGaA/SkyePharma

Latest Information Update: 26 Jul 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck KGaA
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 26 Jul 2006 No development reported - Phase-III for Inflammation in Europe (PO)
  • 13 Oct 2004 Merck KGaA's anti-inflammatory Geomatrix(TM) product is available for partnering in countries outside Germany and Austria, including the USA (http://www.merck.de)
  • 13 Oct 2004 Phase-III clinical trials in Inflammation in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top